Trial Profile
A Randomized, Placebo Controlled, Double Blind, Dose Escalating, Crossover, Safety and Pharmacokinetic Study of AX-024.HCl in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2015
Price :
$35
*
At a glance
- Drugs AX 024 (Primary)
- Indications Asthma; Multiple sclerosis
- Focus Adverse reactions
- Sponsors Artax Biopharma
- 13 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 24 Sep 2014 New trial record